Sponsored Research Newsflash 13 October 2020

Europace with once strong quarterly transaction figures

Hypoport has published its transaction figures for Q3. Europace 9M transaction figures rates were strong with an increase of the transaction volume by 30% yoy, which was however slightly lower than in H1 (+31% yoy). Transaction volume mortgage finance at Europace increased by 34% yoy in 9M; the slightly lower growth rate versus H1 2020 (+36% yoy) can be presumably partly explained by a base effect as Q3 2019 has been a particularly strong quarter. Positively, total Europace transaction volume per day was up by 28% yoy in Q3 which was a slight improvement versus Q2 (+27% yoy). This shows that the underlying strong growth trend remained intact. At Dr. Klein (retail customers) financing volume was up by 10% yoy in Q3 which was lower than in Q2 (+22% yoy). The real estate platform showed a strong performance with an increase of values of properties valued by 50% yoy (Q2 '20: +10% yoy). All in all, good transaction figures for Q3, Europace once again strong, Dr. Klein somewhat weaker compared to Q2. We stick to our Buy recommendation.

Europace transaction figures in more detail

Mortgage finance transaction volume was up by 31% yoy (Q2 '20: +33% yoy) to EUR 19.1bn in Q3, building finance transaction volume increased by 18% yoy (Q2 '20: +20% yoy) to EUR 3.6bn and personal loans transaction volume increased by 1% yoy to EUR 0.9bn, which was a clear improvement versus Q2 2020 (-7% yoy). Finmas reached an increase of the transaction volume by 28% yoy (Q2 '20: +20%) and Genopace an increase of 50% yoy (Q2 '20: +80%). The somewhat lower yoy growth of Genopace is presumably mainly due to the fact that the growth rates sooner or later have to decline with growing absolute levels.

Dr Philipp Häßler CFA +49 69 58997 414, philipp.haessler@paretosec.com

Pareto Securities AS has been paid by the issuer to produce this research report. This material is considered by Pareto Securities to qualify as an acceptable minor non-monetary benefit according to the EU MIFID 2 directive.